Renee Maloney
Family · Bethesda, MDNPI 1720528631
Payments from drug & device makers
Across 111 payments — averaging $52.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Incyte Corporation$305
- AbbVie$274
- Seagen Inc.$259
- Johnson & Johnson$231
- Merck$216
- plus $2K from 25 others
What the payments were for
- Consulting fees$64811%
- Food & beverage$2,60045%
- Education$4127%
- Other$2,18037%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 28 | $2,917 |
| Incyte Corporation | 10 | $305 |
| AbbVie | 6 | $274 |
| Seagen Inc. | 6 | $259 |
| Johnson & Johnson | 7 | $231 |
| Merck | 8 | $216 |
| Daiichi Sankyo Inc. | 6 | $198 |
| AVEO Pharmaceuticals, Inc. | 3 | $173 |
| Epizyme, Inc. | 1 | $124 |
| AstraZeneca | 1 | $122 |
| Intera Oncology, Inc | 1 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $95 |
| Pfizer | 4 | $94 |
| GSK | 3 | $82 |
| Gilead | 3 | $74 |
| Bristol Myers Squibb | 2 | $60 |
| Lilly USA, LLC | 2 | $59 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Genentech USA, Inc. | 2 | $47 |
| Astellas Pharma US Inc | 2 | $45 |
| Stemline Therapeutics Inc. | 1 | $40 |
| Spectrum Pharmaceuticals Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Tempus AI, Inc | 1 | $29 |
| Sobi, Inc | 1 | $28 |
| Eisai Inc. | 1 | $27 |
| Beigene USA, Inc. | 1 | $27 |
| Mirati Therapeutics, Inc. | 1 | $27 |
| Coherus Oncology, Inc. | 1 | $26 |
| Taiho Oncology, Inc. | 1 | $23 |
| Acrotech Biopharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,839 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $10,657 |
| Acyclovir | 21 | $1,255 |
| Dexamethasone | 29 | $526 |
| Ondansetron OdtOndansetron | 36 | $496 |
| Anastrozole | 18 | $460 |
| Oxycodone Hcl | 24 | $356 |
| Letrozole | 17 | $335 |
| Prochlorperazine Maleate | 30 | $265 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 16 | $178 |
| Pregabalin | 11 | $130 |
| Tramadol Hcl | 16 | $112 |
| Lorazepam | 21 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $94 | $10,65715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Bethesda
- Diana RapaloBethesda$13K
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.